StreetInsider.com News Articles

MAIA Biotechnology reports 90.5% disease control rate in lung cancer trial

Wed, 08 Jul 2026 09:45:27 -0400

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced initial efficacy data from Part C of its Phase 2 THIO-101 clinical trial, evaluating ateganosine as a third-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

The data showed a disease control rate (DCR) of 90.5%, representing 19 out of 21 patients in the efficacy evaluable population who had at least one tumor scan after starting treatment. Patients in the trial receive ateganosine followed by cemiplimab (Libtayo®) in 21-day cycles. Current chemotherapy treatments deliver an approximate 25-35% disease control rate, according to the company.

All patients enrolled in Part C had previously received

MAIA Biotechnology reports 90.5% disease control rate in lung cancer trial

Wed, 08 Jul 2026 09:45:27 -0400

All patients enrolled in Part C had previously received

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: CHAOUKI STEVEN M

Thu, 02 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260702/26727972.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: CHAOUKI STEVEN M

Thu, 02 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260702/26727972.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Guerrero Ramiro

Thu, 02 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260702/26727903.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Guerrero Ramiro

Thu, 02 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260702/26727903.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Louie Ngar Yee

Thu, 02 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26727868.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Louie Ngar Yee

Thu, 02 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26727868.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Luput Cristian

Thu, 02 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260702/26727832.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Luput Cristian

Thu, 02 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260702/26727832.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Smith Stan

Thu, 02 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26727803.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Smith Stan

Thu, 02 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26727803.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Theagene Jean-Manasse

Thu, 02 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260702/26727755.html

Form 4 MAIA Biotechnology, Inc. For: Jun 30 Filed by: Theagene Jean-Manasse

Thu, 02 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260702/26727755.html

MAIA Biotechnology receives FDA clearance for lung cancer trial expansion

Wed, 03 Jun 2026 09:45:46 -0400

MAIA Biotechnology Inc. (NYSE American: MAIA) announced that the U.S. Food and Drug Administration cleared an amendment to its investigational new drug application, enabling the company to open U.S. enrollment for the expansion of its Phase 2 THIO-101 trial.

The trial evaluates ateganosine, the company's drug candidate, as a treatment for advanced non-small cell lung cancer. The FDA clearance covers updated manufacturing capabilities, including new manufacturers, formulation and storage conditions for ateganosine.

MAIA can now enroll patients in the U.S. for the expansion study targeting patients receiving advanced third-line NSCLC treatment. The THIO-101 study operates at 44 clinical sites across six countries.

MAIA Biotechnology receives FDA clearance for lung cancer trial expansion

Wed, 03 Jun 2026 09:45:46 -0400

Form 4 MAIA Biotechnology, Inc. For: Jun 01 Filed by: Vitoc Vlad

Tue, 02 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260602/26588734.html

Form 4 MAIA Biotechnology, Inc. For: Jun 01 Filed by: Vitoc Vlad

Tue, 02 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260602/26588734.html

Form 4 MAIA Biotechnology, Inc. For: Jun 01 Filed by: Smith Stan

Tue, 02 Jun 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26588706.html

Form 4 MAIA Biotechnology, Inc. For: Jun 01 Filed by: Smith Stan

Tue, 02 Jun 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26588706.html

Form 4 MAIA Biotechnology, Inc. For: Jun 01 Filed by: Gryaznov Sergei

Tue, 02 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26588620.html

Form 4 MAIA Biotechnology, Inc. For: Jun 01 Filed by: Gryaznov Sergei

Tue, 02 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26588620.html

Form 4 MAIA Biotechnology, Inc. For: May 29 Filed by: Vitoc Vlad

Mon, 01 Jun 2026 08:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26580119.html

Form 4 MAIA Biotechnology, Inc. For: May 29 Filed by: Vitoc Vlad

Mon, 01 Jun 2026 08:54:00 -0400

si-local-file:///var/storage/secattach/20260601/26580119.html

Form 4 MAIA Biotechnology, Inc. For: May 29 Filed by: Gryaznov Sergei

Mon, 01 Jun 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260601/26580104.html